氨溴索联合川芎嗪治疗特发性肺纤维化52例

The ambroxol combined with ligustrazine in the treatment of 52 patients with idiopathic pulmonary fibrosis

目的观察氨溴索联合川芎嗪治疗特发性肺纤维化(IPF)的疗效。方法选取102例符合本次研究的患者,随机分为两组,对照组50例,予强的松口服治疗。治疗组52例,予氨溴索雾化吸入联合川芎嗪静脉滴注治疗。疗程均为8周。结果氨溴索雾化吸入联合川芎嗪静脉滴注疗效明显优于对照组。结论氨溴索雾化吸入联合川芎嗪静脉滴注治疗疗效确切,优于传统类固醇激素的治疗方法。

Objective To observe the clinical efficacy of ambroxol combined with ligustrazine in the treatment of idiopathic pulmonary fibrosis （IPF）. Methods 102 patients with IPF were randomly divided into two groups. The control group （n = 50） were given prednisone orally, and the treatment group （n = 52） were treated with ambroxol atomization inhalation combined with ligustrazine intravenous drip. The period of the two groups＇ treatment was 8 weeks. Results The curative effect in the treatment group was better improved than that in the control group with statistical significance （ P 〈 0. 05 ）. Conclusion Ambroxol aerosol inhalation combined with ligustrazine intravenous drip in the treatment of patients with IPF has a pronounced curative effect that is superior to the conventional steroid hormone treatment.